229.00
+0.88%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sartorius
Its shares trade on XETRA under the ticker SRT.DE. It has been listed since 1 April 1999. In the fiscal year to 31 December 2025, it reported revenue of €3.54bn and net income of €154.9m. At that date it held total assets of €9.72bn and shareholders' equity of €2.71bn.
Sartorius AG is a DE-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Goettingen, Niedersachsen. Sartorius AG is a Germany-based supplier of pharmaceutical and laboratory equipment. The company operates through two segments: Bioprocess Solutions and Lab Products and Services. The Bioprocess Solutions segment offers integrated solutions for biopharmaceutical manufacture, such as filters for sterilization of biopharmaceutical media, single-use bags for cell cultivation and storage of biopharmaceuticals, membrane adsorbers for purification in bioprocesses, and filter technology for clarification, among others. The Lab Products and Services segment provides instruments, consumables and services for laboratories, including laboratory balances, laboratory water systems for storage of purified water, electronic pipettes, filter systems for sample preparation and membrane filter systems for sterility testing of parenterals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Apr 1999
- Employees
- 10,637
- Website
- sartorius.de ↗
Leadership
Pay as last reported
- Dr. Lothar KappichChairman of the Supervisory Board, Shareholder Representative, since 2007€284,000
- Dr. Joachim KreuzburgChairman of the Executive Board, Chief Executive Officer€1.6m
- Dr. Michael GrosseChief Executive Officer, Member of the Executive Board
- Dr. Florian FunckChief Financial Officer, Member of the Executive Board€1.8m
- Dr. Rene FaberMember of the Executive Board, Head - Bioprocess Solutions Division€2.0m
- Dr. Alexandra GatzemeyerMember of the Executive Board, Head - Lab Products & Services Division€1.5m
- Prof. Dr. h.c. David EbsworthIndependent Member of the Supervisory Board€82,000
- Dr. Daniela FavocciaIndependent Member of the Supervisory Board, Shareholder Representative€85,000
- Ms. Ilke PanzerIndependent Member of the Supervisory Board, Shareholder Representative€82,000
- Mr. Frank RiemenspergerIndependent Member of the Supervisory Board, Shareholder Representative€82,000
- Prof. Dr. Klaus TruetzschlerIndependent Member of the Supervisory Board, Shareholder Representative€189,000
- Ms. Petra KirchhoffMember of the Supervisory Board, Head of Corporate Communications & IR€82,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 91
- Environment
- 97
- Social
- 99
- Governance
- 77
- Direct emissions (scope 1)
- 20,355 t
- Energy emissions (scope 2)
- 51,872 t
- Value chain emissions (scope 3)
- 645,033 t
- Women in the workforce
- 39%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sartorius AG has established a reputable brand image in the industry, known for its high-quality products and innovative solutions. This enables the company to attract and retain a loyal customer base.
- Sartorius AG offers a wide range of products that cater to various industries, including biotechnology, pharmaceutical, and laboratory equipment. This diversification helps the company to capture multiple revenue streams and reduce dependence on a single market.
- The company heavily invests in research and development activities, enabling it to continuously introduce new and advanced products to the market. This fosters innovation and keeps Sartorius AG at the forefront of technological advancements.
Weaknesses
- Sartorius AG's financial performance is influenced by global economic conditions and market fluctuations. During economic downturns, the demand for its products may decrease, impacting the company's revenue and profitability.
- While Sartorius AG has a strong brand reputation, it may have limited market presence compared to some of its competitors. This may restrict its market share and potential growth opportunities in certain geographic regions.
Opportunities
- The biopharmaceutical industry is experiencing significant growth, driven by factors such as increasing research activities, rising investments in healthcare, and advancements in personalized medicine. Sartorius AG can capitalize on this trend by providing specialized equipment and solutions to meet the growing demand.
- Expansion into emerging markets, such as Asia-Pacific and Latin America, can provide Sartorius AG with new growth opportunities. These regions have a growing biotechnology and pharmaceutical sector, creating a potential market for the company's products.
Threats
- The industry in which Sartorius AG operates is highly competitive, with numerous players vying for market share. The company faces competition from both established companies and new entrants, which can pose challenges to its market position.
- The biopharmaceutical industry is subject to strict regulatory requirements, and non-compliance can lead to penalties and reputational damage. Sartorius AG needs to continually ensure compliance with regulations and industry standards to mitigate legal risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.